^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

RNF43 G659fs

i
Entrez ID:
Related biomarkers:
9ms
Ring Finger 43 Hot-spot Frameshift Mutation G659V in Colorectal Cancer Patients: Report from a Tertiary Cancer Care Hospital in North India. (PubMed, Int J Appl Basic Med Res)
To the best of our knowledge, this is the first study from North India to show the involvement of RNF43 p.G659fs variant in CRC patients. The mutation correlated with MMR protein deficiency and seems to be conferring tumorigenicity independent of the Wnt pathway.
Journal
|
RNF43 (Ring Finger Protein 43)
|
RNF43 mutation • RNF43 G659fs
1year
Canonical Wnt signaling pathway (WSP) alterations in metastatic prostate cancer. (ASCO-GU 2024)
WSP-act prostate cancer demonstrated a pronounced upregulation of ROR1 gene expression, underscoring its potential involvement in the crosstalk between the canonical and non-canonical Wnt signaling pathways. Additionally, the augmented levels of M2 macrophages in WSP-act tumors, combined with the reported role of ROR1 in tumor immunosuppression, suggests that ROR1 may contribute to immune evasion in WSP-act mPCa. Our findings may provide rationale for developing novel therapeutic strategies targeting Wnt-activated prostate cancers.
MSi-H Biomarker • Metastases
|
RNF43 (Ring Finger Protein 43) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • SPOP (Speckle Type BTB/POZ Protein) • RSPO2 (R-Spondin 2)
|
MSI-H/dMMR • ROR1 expression • RNF43 mutation • SPOP mutation • RNF43 G659fs • CTNNB1 expression
|
MI Tumor Seek™
2years
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF metastatic colorectal cancer. (PubMed, Nat Med)
We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRC tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients.
Journal
|
EGFR (Epidermal growth factor receptor) • RNF43 (Ring Finger Protein 43)
|
EGFR mutation • RNF43 mutation • RNF43 G659fs
over2years
A characterization of the most common RNF43 mutations in gastric cancer in vitro and in vivo (EACR 2022)
Conclusion Collectively, our findings indicate that mutations in RNF43 confer gastric cells resistance to DNA damage induced by radiotherapy. In addition, we successfully generated a mouse model to study the effect of RNF43 mutation G659Vfs*41 in gastric carcinogenesis and therapy response.
Preclinical
|
RNF43 (Ring Finger Protein 43)
|
RNF43 mutation • RNF43 G659fs